Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Cerebrolysin

Hydrolyzed Porcine Brain Peptide Complex

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

For its flagship indication, acute ischaemic stroke, the 2020 Cochrane review (CD007026.pub6, 7 studies, 1773 people) found no clinical benefit on death or functional outcome and, on moderate-quality evidence, a signal of increased non-fatal serious adverse events (relative risk about 2.47), which is refuted-leaning. For vascular dementia the 2019 Cochrane review (CD008900.pub3, 6 studies, 597 people) reported modest MMSE and global-function signals but rated the evidence insufficient to recommend routine use, with most trials manufacturer-sponsored and at risk of bias. Alzheimer's data are inconclusive and the moderate-to-severe TBI evidence rests on small, EVER Pharma-sponsored CAPTAIN meta-analyses (about 185 patients), so the honest composite lands at preliminary/mixed rather than the strong multi-country picture the current entry implies.

FDA
Not FDA-approved for any indication; investigational only in the USA (orphan-drug designation for frontotemporal dementia). Approved in Austria, several EU states, Russia, and across Asia.
WADA
Not on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

Porcine-brain-derived complex mixture; not FDA-approved; daily IV/IM injection; Cochrane stroke review associated it with a signal of increased non-fatal serious adverse events.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Cerebrolysin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

An injectable mixture of low-molecular-weight neuropeptides and free amino acids from enzymatically hydrolyzed porcine brain, made by EVER Pharma and approved in over 50 countries for stroke, TBI, and dementia. It is not FDA-approved in the USA, and Cochrane reviews found no benefit for acute ischaemic stroke and only weak, manufacturer-sponsored signals in dementia.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Post-stroke recovery
  • TBI rehabilitation
  • Alzheimer's (positive European trials)

How it is supposed to work

Cerebrolysin is a mixture of small peptides and amino acids extracted from pig brain, designed to imitate the brain’s own growth-and-repair signals, the neurotrophic factors. Rather than acting through one target, it is a multi-component preparation that, in laboratory and animal models, protects neurons from injury, supports their repair, encourages the formation of new neurons, and aids recovery. The underlying idea is appealing: give an injured or aging brain a concentrated dose of the same molecules it normally uses to heal itself.

Cerebrolysin is not a single molecule but a standardized biological preparation derived from porcine brain tissue, roughly 15% low-molecular-weight peptides and 85% free amino acids. It is made by EVER Pharma in Austria and given by injection, and it has been in clinical use since the 1970s. Its nature as a complex, brain-derived mixture is both the source of its broad, neurotrophic-like activity and a reason its precise mechanism is hard to pin down.

Type
Porcine brain peptide mixture
Action
Neurotrophic-mimetic
Route
Injection (IV/IM)
Approved in
50+ countries
FDA
Not approved
In use since
1970s

Widely Approved, Genuinely Contested

Cerebrolysin is approved in more than 50 countries for stroke, brain injury and dementia, and has been tested in over 200 trials involving more than 15,000 patients, which sounds definitive. But the honest picture is that the evidence is genuinely contested. The most rigorous independent assessments, the Cochrane reviews, found no clear benefit for stroke, and a 2023 Cochrane review reported no benefit on survival together with a statistically significant increase in non-fatal serious adverse events. Much of the positive evidence comes from a single interested manufacturer and affiliated research groups, with documented concerns about publication bias and, in some cases, research integrity. So the data ranges from genuinely promising to deeply ambiguous, and cannot confidently separate a real treatment effect from methodological limitations and sponsor bias. Being widely used and approved is not the same as being clearly proven.

Safety in detail

The 2020 Cochrane acute-ischaemic-stroke review reported no reduction in death or disability and, on moderate-quality evidence, a signal of increased non-fatal serious adverse events with Cerebrolysin versus placebo. Much of the positive Cerebrolysin literature is sponsored by the manufacturer, which Cochrane cites as a risk-of-bias concern. As a porcine-brain-derived biological, batch composition is not fully characterized.

  • Most individual studies and manufacturer-affiliated meta-analyses report excellent tolerability, with adverse events rare and similar to placebo.
  • However, the independent 2023 Cochrane review found a statistically significant increase in non-fatal serious adverse events, a discrepancy worth weighing seriously.
  • It is given by injection in clinical settings; off-label self-injection outside medical care adds risk.
  • It is approved abroad but not in the US, UK or Australia, so Western off-label use relies on gray-market product.
  • It is derived from pig brain tissue, a consideration for some users.

Children and teenagers

In some countries Cerebrolysin is used within pediatric neurology for certain developmental and cognitive conditions under medical supervision, a legitimate clinical context where it is approved. That is distinct from off-label nootropic use in healthy minors, which has no oversight and rests on contested evidence even in adults. Any pediatric use belongs strictly within approved clinical care.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Cerebrolysin’s commercial center is EVER Pharma, the Austrian manufacturer that sells it as an approved drug across more than 50 countries and is connected to much of its supportive research. Around the unapproved Western market sits the gray-market and clinic economy supplying it for off-label nootropic and anti-aging use. The notable feature here is that the manufacturer is also the dominant source of the positive evidence, which is precisely the sponsor-shaped-evidence pattern that warrants caution.

How we got here

Cerebrolysin is a porcine-brain-derived peptide mixture produced by EVER Neuro Pharma through standardized enzymatic proteolysis of lipid-free pig brain proteins. It is approved and marketed in dozens of countries across Eurasia for stroke, dementia, and traumatic brain injury, and remains an investigational agent that is not FDA-approved in the United States.

Cerebrolysin was developed by EVER Pharma in Austria and has been used since the 1970s. Through the 1980s and 1990s it gained approval across Russia, Eastern Europe, China and other Asian countries, where neurologists adopted it widely for stroke and dementia. The 2000s brought larger randomized trials, and the CARS stroke studies and CAPTAIN traumatic-brain-injury series offered the most rigorous data. Yet independent Cochrane reviews repeatedly found the benefit unconvincing, a 2023 review flagged a safety signal, and research-integrity questions touched some studies, leaving a drug that is simultaneously widely used and seriously contested, while Western users adopted it off-label as a nootropic.

  1. 1970sEVER Pharma develops Cerebrolysin; clinical use begins.
  2. 1980s-1990sApproved and widely adopted across Russia, Eastern Europe, China and Asia for stroke and dementia.
  3. 2000s-2021Larger trials, including the CARS stroke and CAPTAIN traumatic-brain-injury studies, report benefit.
  4. 2017-2023Independent Cochrane reviews find no clear benefit and, in 2023, a safety signal.
  5. 2010s-2020sAdopted off-label as a nootropic in Western countries where it is unapproved.

The numbers behind the grade

Type
Brain peptide mixture
Source
Porcine brain
Approved in
50+ countries
FDA
Not approved
Trials
200+ / 15,000+ patients
Independent evidence
Contested

The people taking it

The most-studied brain-peptide preparation, approved and widely used across more than 50 countries for decades and increasingly known as an off-label nootropic, but with genuinely contested evidence.

Cerebrolysin’s approved users are patients with stroke, traumatic brain injury and dementia, concentrated in Russia, Eastern Europe, China and other parts of Asia, the Middle East and Latin America. Its off-label users, mainly in Western countries where it is not approved, are nootropic and anti-aging seekers and people hoping to aid recovery or slow cognitive decline. The clinical population is genuine; the off-label population leans on an even thinner evidence base.

Approved and used across 50+ countries for stroke, brain injury and dementia, and used off-label in the West as a nootropic. Backed by a huge trial base but contested by the most rigorous independent reviews.

Set against the alternatives

Against gray-market nootropics like Semax and Selank, Cerebrolysin is an actually approved neurological drug in many countries with a vast trial base, which sets it apart, yet its independent evidence is more contested than that approval implies. Against proven acute stroke treatments such as clot-busting drugs and thrombectomy, Cerebrolysin is at best an adjunct with disputed benefit, not a primary therapy. And against the broader concept of neurotrophic therapy, mimicking BDNF and similar factors, it is a crude, real-world attempt at a sound idea, which may be part of why its effects are inconsistent. Its strength is genuine approval and enormous study; its weakness is that the most rigorous, independent evidence does not clearly support it.

What we do not know

  • Whether Cerebrolysin truly works, given the conflict between sponsor-affiliated positive data and skeptical independent reviews.
  • How seriously to weigh the Cochrane signal of increased serious adverse events.
  • Whether a large, fully independent trial would confirm any benefit.
  • Whether its off-label nootropic use has any real basis, given even thinner evidence.

What could change

Ongoing trialsNew studies continue to test specific stroke and recovery scenarios.Evidence-quality debateThe central question is whether independent data can confirm or refute the sponsor-affiliated findings.Safety signalThe Cochrane finding of increased serious adverse events warrants further scrutiny.Off-label nootropic useContinued Western gray-market use on thin evidence.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Where approved, it is obtained as a prescription drug and administered medically. In countries where it is not approved, it is available only gray-market for off-label use, which is not an approved route. For stroke or dementia, proven treatments exist and the evidence for Cerebrolysin is contested, so a clinician’s guidance matters; gray-market users should insist on tested product.

Where approved, it is an established and reasonably affordable clinical drug. In non-approving countries, gray-market vials are moderately priced. Cost aside, the central issue is whether it works, which the independent evidence leaves unresolved.

The approved drug comes from EVER Pharma under regulation in authorized markets. Gray-market supply for non-approving countries comes from less controlled channels, where quality assurance is limited and a certificate of analysis is the only check.

EVER Pharma (approved)Manufactures and sells Cerebrolysin as a regulated drug in the many countries where it is approved, a controlled chain.China and gray-marketSupply the off-label Western market, where it is not approved, as research or gray-market material.Clinic channelSome clinics in non-approved countries offer it off-label for cognitive and recovery uses.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Cerebrolysin.

Nothing outstanding on this one.

Sources

The studies that matter

  • CARS-1 and CARS-22010s

    Two randomized stroke trials reported early benefit on motor recovery as an adjunct to rehabilitation, though conducted with manufacturer involvement.

  • CAPTAIN trials (TBI)2015-2021

    The most rigorous investigation in traumatic brain injury, reporting functional improvement, part of the supportive but sponsor-affiliated evidence base.

  • Cochrane reviews of stroke2017

    Independent Cochrane analysis found no convincing benefit of Cerebrolysin in acute ischemic stroke.

  • 2023 Cochrane review2023

    Pooling 7 trials and 1,773 patients, it found no benefit on all-cause death and a statistically significant increase in non-fatal serious adverse events, a notable safety signal.

  • Heiss et al, Asia stroke trial2012

    A large trial that cast doubt on benefit except possibly in severe stroke, contributing to the ambiguity.